- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT06326047
Výzkumná studie porovnávající, jak dobře různé dávky léku NN0519-0130 snižují hladinu cukru v krvi u lidí s diabetem 2.
Zkoumání bezpečnosti a účinnosti podávání jednou týdně NNC0519-0130 u účastníků s diabetem 2. typu – studie pro zjištění dávky
This study will look at how well a new medicine called NNC0519-0130 helps people with type 2 diabetes lower their blood sugar and body weight. The study will test up to 7 different doses of NNC0519-0130. Which treatment participant will get is decided by chance. Participants will take 1-3 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 40 weeks.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 2
Kontakty a umístění
Studijní místa
-
-
New South Wales
-
Campbelltown, New South Wales, Austrálie, 2560
- Campbelltown Hospital
-
Macquarie Park, New South Wales, Austrálie, 2109
- Macquarie University - Clinical Trials Unit
-
St Leonards, New South Wales, Austrálie, 2065
- Royal North Shore Hospital
-
Sydney, New South Wales, Austrálie, 2148
- Western Endocrine Blacktown
-
Sydney, New South Wales, Austrálie, 2148
- Roger Chih Yu Chen
-
Wollongong, New South Wales, Austrálie, 2500
- Illawarra Diabetes Service Clinical Trials & Research Unit
-
-
Queensland
-
Birtinya, Queensland, Austrálie, 4575
- University of Sunshine Coast - Vitality Village
-
Meadowbrook, Queensland, Austrálie, 4131
- Logan Hospital
-
-
South Australia
-
Oaklands Park, South Australia, Austrálie, 5046
- Southern Adelaide Diabetes & Endocrine Services
-
-
Victoria
-
Box Hill, Victoria, Austrálie, 3128
- Eastern Clinical Research Unit Box Hill
-
Camberwell, Victoria, Austrálie, 3124
- Emeritus Research Melbourne
-
Heidelberg Heights, Victoria, Austrálie, 3081
- Austin Health, Metabolic Disorders Centre
-
Parkville, Victoria, Austrálie, 3050
- The Royal Melbourne Hospital
-
Parkville, Victoria, Austrálie, 3050
- The Royal Melbourne Hospital - Diabetes & Endocrinology Department
-
-
Western Australia
-
Fremantle, Western Australia, Austrálie, 6160
- Fremantle Hospital
-
-
-
-
-
Bengaluru, Indie, 560054
- MS Ramaiah
-
New Delhi, Indie, 110001
- Lady Hardinge Medical College
-
-
Karnataka
-
Bangalore, Karnataka, Indie, 560092
- Life Care Hospital and Research Centre
-
-
Kerala
-
Kochi, Kerala, Indie, 682041
- Amrita Institute Of Medical Sciences & Research Centre
-
-
Madhya Pradesh
-
Indore, Madhya Pradesh, Indie, 452010
- TOTALL Diabetes Hormone Institute
-
-
Maharashtra
-
Mumbai, Maharashtra, Indie, 400012
- Seth GS Medical College & KEM Hospital
-
Pune, Maharashtra, Indie, 411021
- Chellaram Diabetes Institute
-
-
Rajasthan
-
Jaipur, Rajasthan, Indie, 302006
- Diabetes, Thyroid and Endocrine Centre
-
-
Tamil Nadu
-
Vellore, Tamil Nadu, Indie, 632004
- Christian Medical College Hospital, Vellore
-
-
Telangana
-
Hyderabad, Telangana, Indie, 500082
- Diabetes Research Center, Hyderabad
-
-
-
-
-
Chiba, Japonsko, 261-0004
- Tokuyama clinic_Diabetic internal medicine
-
Soka-shi, Saitama, Japonsko, 340-0015
- Soka Sugiura Internal Medicine Clinic
-
Tokyo, Japonsko, 104-0031
- Fukuwa Clinic
-
Tokyo, Japonsko, 103-0027
- Tokyo-Eki Center-building Clinic_Internal Medicine
-
Tokyo, Japonsko, 104-0031
- Fukuwa Clinic_Internal Medicine
-
-
-
-
Free State
-
Bloemfontein, Free State, Jižní Afrika, 9301
- Josha Research
-
-
Gauteng
-
Johannesburg, Gauteng, Jižní Afrika, 2013
- Wits Bara Clinical Trial Site
-
Midrand, Gauteng, Jižní Afrika, 1685
- Dr A Jacovides and Partners Inc
-
-
KwaZulu-Natal
-
Durban, KwaZulu-Natal, Jižní Afrika, 4450
- Dr Pillay's Rooms
-
eMkhomazi, KwaZulu-Natal, Jižní Afrika, 4170
- Dr T Padayachee
-
-
-
-
-
Seoul, Jižní Korea, 05505
- Asan Medical Center
-
Seoul, Jižní Korea, 01830
- Nowon Eulji Medical Center, Eulji University
-
Seoul, Jižní Korea, 03181
- Kangbuk Samsung Hospital
-
Seoul, Jižní Korea, 02841
- Korea University Anam Hospital
-
-
Gyeonggi-do
-
Seongnam-si, Gyeonggi-do, Jižní Korea, 13620
- Seoul National University Bundang Hospital
-
-
-
-
-
Québec, Kanada, G1V 4T3
- Diex Recherche Quebec
-
-
British Columbia
-
Kelowna, British Columbia, Kanada, V1Y 1Z9
- OCT Research ULC (dba Okanagan Clinical Trials)
-
Richmond, British Columbia, Kanada, V6V 2L1
- OCT Research ULC (dba Okanagan Clinical Trials)
-
Victoria, British Columbia, Kanada, V8V 4A1
- Cook Street Medical Clinic
-
-
New Brunswick
-
Moncton, New Brunswick, Kanada, E1G 1A7
- G.A. Research Associates Ltd.
-
-
Nova Scotia
-
Halifax, Nova Scotia, Kanada, B3H 1V7
- Nova Scotia Hlth Halifax
-
-
Ontario
-
Barrie, Ontario, Kanada, L4N 7L3
- Centricity Research Barrie
-
Hamilton, Ontario, Kanada, L8L 5G8
- Wharton Medical Clinic Clinical Trials (Hamilton)
-
Sarnia, Ontario, Kanada, N7T 4X3
- London Road Diagnostic Clinic and Medical Centre
-
Toronto, Ontario, Kanada, M4G 3E8
- Centricity Research Toronto
-
Toronto, Ontario, Kanada, M9V 4B4
- Albion Finch Medical Centre
-
-
Quebec
-
Lévis, Quebec, Kanada, G6W 0M5
- Centricity Research Quebec City
-
Mirabel, Quebec, Kanada, J7J 2K8
- Centricity Research Mirabel
-
Montreal, Quebec, Kanada, H1Y 3H5
- Recherche GCP Research
-
Saint-Laurent, Quebec, Kanada, H4T 1Z9
- Centricity Research Ville St. Laurent VSL
-
-
-
-
California
-
Chula Vista, California, Spojené státy, 91911
- Velocity Clin Res-Chula Vista
-
Fresno, California, Spojené státy, 93720
- Valley Research
-
Inglewood, California, Spojené státy, 90301
- 310 Clinical Research
-
La Mesa, California, Spojené státy, 91942
- Velocity Clin Res San Diego
-
Lancaster, California, Spojené státy, 93534
- First Valley Med Grp Lancaster
-
Lomita, California, Spojené státy, 90717
- Torrance Clin Res Inst, Inc.
-
Los Alamitos, California, Spojené státy, 90720
- Pacific Clinical Studies
-
Los Angeles, California, Spojené státy, 90057
- Velocity Clinical Research Westlake
-
Montclair, California, Spojené státy, 91763
- Catalina Research Institute, LLC
-
San Diego, California, Spojené státy, 92123
- Artemis Insitute for Clin Res
-
Toluca Lake, California, Spojené státy, 91602
- Med Partners, Inc.
-
Torrance, California, Spojené státy, 90505
- UCLA Health Southbay Endocrine
-
Tustin, California, Spojené státy, 92780
- University Clin Investigators
-
Walnut Creek, California, Spojené státy, 94598
- Diablo Clinical Research, Inc.
-
-
Colorado
-
Aurora, Colorado, Spojené státy, 80045
- University of Colorado Hospital
-
-
Florida
-
Clearwater, Florida, Spojené státy, 33756
- Innovative Research of W Florida Inc.
-
Clearwater, Florida, Spojené státy, 33756
- Innovative Research of W FL
-
Miami, Florida, Spojené státy, 33183
- International Research Associates, LLC_Miami
-
-
Georgia
-
Columbus, Georgia, Spojené státy, 31904
- Centricity Research
-
-
Idaho
-
Blackfoot, Idaho, Spojené státy, 83221
- Elite Clinical Trials
-
-
Illinois
-
Peoria, Illinois, Spojené státy, 61603
- Methodist Medical Center of Illinois
-
-
Iowa
-
Iowa City, Iowa, Spojené státy, 52242
- University of Iowa
-
-
Maryland
-
Columbia, Maryland, Spojené státy, 21045
- Centennial Medical Group
-
Oxon Hill, Maryland, Spojené státy, 20745
- MD Medical Research
-
Rockville, Maryland, Spojené státy, 20852
- Endo And Metab Cons
-
-
Missouri
-
Springfield, Missouri, Spojené státy, 65807
- Clinvest Research
-
-
Montana
-
Butte, Montana, Spojené státy, 59701
- Mercury Str Med Grp, PLLC
-
-
Nebraska
-
Lincoln, Nebraska, Spojené státy, 68510
- Velocity Clinical Research Lincoln
-
-
Nevada
-
Las Vegas, Nevada, Spojené státy, 89148
- Palm Research Center Inc-Vegas
-
Las Vegas, Nevada, Spojené státy, 89109
- Excel Clinical Network
-
-
New York
-
Binghamton, New York, Spojené státy, 13905
- Velocity Clinical Research Binghamton
-
-
North Carolina
-
Greensboro, North Carolina, Spojené státy, 27408
- PharmQuest Life Sciences LLC
-
Wilmington, North Carolina, Spojené státy, 28401
- Accellacare Wilmington
-
-
Ohio
-
Canton, Ohio, Spojené státy, 44718
- Diab & Endo Assoc of Stark Co
-
Cincinnati, Ohio, Spojené státy, 45242
- Velocity Clin Res_Cincinnati
-
Cincinnati, Ohio, Spojené státy, 45246
- Velocity Clinical Research Springdale
-
Dayton, Ohio, Spojené státy, 45439
- Providence Health Partners Ctr
-
Maumee, Ohio, Spojené státy, 43537
- Advanced Med Res Maumee
-
-
Oregon
-
Grants Pass, Oregon, Spojené státy, 97527
- Velocity Clin Res Grants Pass
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Spojené státy, 19114
- Tristar Clin Investigations, PC
-
Pittsburgh, Pennsylvania, Spojené státy, 15243
- Preferred Primary Care Physicians Inc.
-
Uniontown, Pennsylvania, Spojené státy, 15401
- Preferred Primary Care Physicians, Inc.
-
-
Texas
-
Abilene, Texas, Spojené státy, 79606
- Velocity Clinical Research Abilene
-
Austin, Texas, Spojené státy, 78759
- Velocity Clin Res Austin
-
Dallas, Texas, Spojené státy, 75390
- UT Southwestern Med Center
-
Dallas, Texas, Spojené státy, 75230
- Velocity Clinical Res-Dallas
-
Dallas, Texas, Spojené státy, 75230
- Zenos Clinical research
-
Forney, Texas, Spojené státy, 75126
- Care United Research, LLC
-
Houston, Texas, Spojené státy, 77004
- Endocrine Associates Houston
-
Houston, Texas, Spojené státy, 77043
- Biopharma Informatic_Houston
-
Irving, Texas, Spojené státy, 75039
- Tekton Research
-
Lewisville, Texas, Spojené státy, 75057
- Epic Clinical Research
-
Shavano Park, Texas, Spojené státy, 78231
- Consano Clinical Research, LLC
-
-
Virginia
-
Burke, Virginia, Spojené státy, 22015
- Burke Internal Medicine & Research
-
Newport News, Virginia, Spojené státy, 23606
- TPMG Clinical Research
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Female of non-childbearing potential, or male.
- For United States (US) only: Female of childbearing potential using highly effective non-systemic methods of contraception with low user-dependency and willingness to continue using it through-out the study or male.
- Age 18-75 years (both inclusive) at the time of signing the informed consent.
- Diagnosed with type 2 diabetes mellitus greater than or equal 180 days before screening.
- Stable daily dose(s) more than or equal 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without sodium-glucose co-transporter 2 (SGLT2) inhibitor.
- Glycated haemoglobin (HbA1c) of 7.5-10.0% (58-86 millimoles per moles (mmol/mol)) (both inclusive) as assessed by central laboratory at screening.
- Body mass index (BMI) greater than or equal 23.0 kilograms per meter square (kg/m^2).
Exclusion Criteria:
- Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
- Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Čtyřnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Dosing scheme A (NNC0519-0130)
Participants will receive NNC0519-0130 at 3 dose levels once weekly (QW) as subcutaneous (s.c.) injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Komparátor placeba: Dosing scheme A (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Experimentální: Dosing scheme B (NNC0519-0130)
Participants will receive NNC0519-0130 at 3 dose levels once weekly (QW) as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Komparátor placeba: Dosing scheme B (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Experimentální: Dosing scheme C (NNC0519-0130)
Participants will receive NNC0519-0130 at 5 dose levels once weekly as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Komparátor placeba: Dosing scheme C (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Experimentální: Dosing scheme D (NNC0519-0130)
Participants will receive NNC0519-0130 at 5 dose levels once weekly as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Komparátor placeba: Dosing scheme D (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Experimentální: Dosing scheme E (NNC0519-0130)
Participants will receive NNC0519-0130 at 7 dose levels once weekly as s.c. injection in dose escalating manner. |
NNC0519-0130 will be administered subcutaneously. |
|
Komparátor placeba: Dosing scheme E (Placebo)
Participants will receive NNC0519-0130 matched placebo once weekly s.c. for 3 periods. |
Placebo will be administered subcutaneously. |
|
Aktivní komparátor: Dosing scheme F (tirzepatide)
Participants will receive tirzepatide at 6 dose levels once weekly as s.c. injection in dose escalating manner. |
Trizepatide will be administered subcutaneously. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Change in Glycated haemoglobin (HbA1c)
Časové okno: From baseline (week 0) to 12 weeks on a given maintenance dose
|
Measured as percentage point (%-point) |
From baseline (week 0) to 12 weeks on a given maintenance dose
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Change in Glycated haemoglobin (HbA1c)
Časové okno: From baseline (week 0) to end of treatment (week 36)
|
Measured as percentage point (%-point) |
From baseline (week 0) to end of treatment (week 36)
|
|
Relative change in body weight
Časové okno: From baseline (week 0) to end of treatment (week 36)
|
Measured as percentage (%) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in body weight
Časové okno: From baseline (week 0) to end of treatment (week 36)
|
Measured as kilograms (kg) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in fasting plasma glucose (FPG)
Časové okno: From baseline (week 0) to 12 weeks on a given maintenance dose
|
Measured as millimoles per liter (mmol/L) |
From baseline (week 0) to 12 weeks on a given maintenance dose
|
|
Continuous glucose monitoring (CGM): Change in time in range (TIR) 3.9-10.0 millimoles per liter (mmol/L) (70-180 milligrams per deciliter (mg/dL))
Časové okno: From baseline (week -2 to week 0) to week 22-24 and week 34-36, respectively
|
Measured as percentage point (%-point) |
From baseline (week -2 to week 0) to week 22-24 and week 34-36, respectively
|
|
Change in waist circumference
Časové okno: From baseline (week 0) to end of treatment (week 36)
|
Measured as centimeter (cm) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in systolic blood pressure (SBP)
Časové okno: From baseline (week 0) to end of treatment (week 36)
|
Measured as millimeters of mercury (mmHg) |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high sensitivity C-Reactive Protein (hsCRP)
Časové okno: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in total cholesterol
Časové okno: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high-density lipoprotein (HDL) cholesterol
Časové okno: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in low-density lipoprotein (LDL) cholesterol
Časové okno: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in triglycerides
Časové okno: From baseline (week 0) to end of treatment (week 36)
|
Measured as ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Number of adverse events
Časové okno: From baseline (week 0) to end of study (week 40)
|
Measured as number of events |
From baseline (week 0) to end of study (week 40)
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Ředitel studie: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- NN9541-4945
- U1111-1291-9196 (Jiný identifikátor: World Health Organization (WHO))
- jRCT2031230704 (Identifikátor registru: JRCT)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .